Diabetes

January 6, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Cilostazol, a drug used in the treatment of peripheral vascular disease,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 5/January/2018, 11.27 pm

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
January 6, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Hydralazine,  an anti-hypertensive drug, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/January/2017, 10.53 am

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 4, 2018

Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMVK1) encompassing Pyridoxamine (PM-Vitamin B6) and Phytonadione/Mephyton/Vitamin-K1 (VK1) decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 4/January/2017, 7.47 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]
January 3, 2018

Vitamin-based therapy for Metabolic diseases: A pharmaceutical mixture [PMFA] encompassing Pyridoxamine(PM) and Folic acid (FA) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 3/January/2017, 9.43 am

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June […]